http://purl.org/np/RAZFqdakeG... RAZFqdakeG

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Vincent Emonet

2022-09-16T11:53:49.145Z

http://purl.org/np/RAZFqdakeG... RAZFqdakeG

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

Sertraline has shown efficacy and safety at doses of 50-200 mg/day [72] in treating phobic-related states, with a greater reduction in symptoms related to anxiety/fear, physical symptoms and avoidance behaviors [73]. Clinical improvements in obsessive symptoms and phobic behavior have been achieved with long-term therapy, with a good tolerability profile. A rapid sertraline titration up to 200 mg/day correlated with fast response rates. A 20-week study with sertraline 50-200 mg/day produced significant improvements both in functioning and social skills [74]. Stable sertraline treatment guaranteed lower recurrence rates, and a general improvement in quality of life. Placebo-controlled studies consistently showed sertraline-related treatment response [72, 75, 76], although with one exception [77]. Treatment of refractory OCD with high doses of sertraline (250-400 mg/day) resulted in a significant symptom improvement and a similar rate of adverse events observed with a 200 mg/day dose [78].

Vincent Emonet

2022-09-16T11:53:49.145Z

http://purl.org/np/RAZFqdakeG... RAZFqdakeG

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/MONDO_0008114 MONDO_0008114

Vincent Emonet

2022-09-16T11:53:49.145Z

http://purl.org/np/RAZFqdakeG... RAZFqdakeG

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Vincent Emonet

2022-09-16T11:53:49.145Z

http://purl.org/np/RAZFqdakeG... RAZFqdakeG

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

http://identifiers.org/drugbank/DB01104 DB01104

Vincent Emonet

2022-09-16T11:53:49.145Z

http://purl.org/np/RAZFqdakeG... RAZFqdakeG

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/has_population_context has_population_context

http://purl.org/np/RAZFqdakeG...#context context

Vincent Emonet

2022-09-16T11:53:49.145Z

http://purl.org/np/RAZFqdakeG... RAZFqdakeG

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/category category

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Vincent Emonet

2022-09-16T11:53:49.145Z

http://purl.org/np/RAZFqdakeG... RAZFqdakeG

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/aggregator_knowledge_source aggregator_knowledge_source

https://w3id.org/biolink/infores/knowledge-collaboratory knowledge-collaboratory

Vincent Emonet

2022-09-16T11:53:49.145Z

http://purl.org/np/RAZFqdakeG... RAZFqdakeG

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/publications publications

http://www.ncbi.nlm.nih.gov/pubmed/30101713 pubmed/30101713

Vincent Emonet

2022-09-16T11:53:49.145Z

http://purl.org/np/RAZFqdakeG... RAZFqdakeG

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

http://purl.obolibrary.org/obo/NCIT_C94303 NCIT_C94303

Vincent Emonet

2022-09-16T11:53:49.145Z